Get the Stockscreener App
176.50
1.02%
1.78
Beigene Ltd Adr stock is traded at $176.50, with a volume of 332.90K.
It is up +1.02% in the last 24 hours and down -9.14% over the past month.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
See More
Previous Close:
$174.72
Open:
$176.29
24h Volume:
332.90K
Relative Volume:
0.90
Market Cap:
$18.79B
Revenue:
$3.32B
Net Income/Loss:
$-860.46M
P/E Ratio:
-10.57
EPS:
-16.6978
Net Cash Flow:
$-1.04B
1W Performance:
-1.59%
1M Performance:
-9.14%
6M Performance:
+13.48%
1Y Performance:
+0.71%
1-Day Range:
$175.80
$179.25
1-Week Range:
$170.99
$180.00
52-Week Range:
$126.97
$248.16
Beigene Ltd Adr Stock (BGNE) Company Profile
Name
Beigene Ltd Adr
Sector
Industry
Phone
13459494123
Address
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Compare BGNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BGNE
Beigene Ltd Adr
|
176.50 | 18.79B | 3.32B | -860.46M | -1.04B | -8.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Beigene Ltd Adr Stock (BGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-24 | Resumed | Morgan Stanley | Overweight |
| Sep-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-06-24 | Resumed | JP Morgan | Overweight |
| Sep-12-23 | Initiated | Macquarie | Outperform |
| Aug-17-23 | Initiated | Jefferies | Buy |
| Jul-17-23 | Initiated | Citigroup | Buy |
| Jun-30-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-12-23 | Initiated | Daiwa Securities | Buy |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-09-22 | Resumed | JP Morgan | Overweight |
| Mar-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-07-22 | Initiated | Deutsche Bank | Buy |
| Oct-12-21 | Initiated | Bernstein | Outperform |
| Oct-06-21 | Upgrade | CLSA | Underperform → Buy |
| Mar-08-21 | Initiated | China Renaissance | Buy |
| Mar-01-21 | Downgrade | CLSA | Outperform → Underperform |
| Nov-09-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-06-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-06-20 | Downgrade | Piper Sandler | Neutral → Underweight |
| Jul-10-20 | Downgrade | CLSA | Buy → Outperform |
| Mar-13-20 | Upgrade | Macquarie | Underperform → Neutral |
| Feb-18-20 | Resumed | Goldman | Buy |
| Jan-17-20 | Upgrade | CLSA | Outperform → Buy |
| Jan-17-20 | Resumed | Morgan Stanley | Overweight |
| Dec-16-19 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-16-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Nov-19-19 | Downgrade | UBS | Buy → Neutral |
| Nov-13-19 | Downgrade | CLSA | Buy → Outperform |
| Nov-04-19 | Reiterated | Maxim Group | Buy |
| Jun-04-19 | Initiated | Bernstein | Outperform |
| May-10-19 | Upgrade | CLSA | Outperform → Buy |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Jan-04-19 | Downgrade | CLSA | Buy → Outperform |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Sep-25-18 | Initiated | Leerink Partners | Outperform |
| May-17-18 | Reiterated | Maxim Group | Buy |
View All
Beigene Ltd Adr Stock (BGNE) Latest News
BeiGene shares reiterate Buy rating on robust oncology pipeline - Investing.com
Weekly Upgrades and Downgrades - InvestorPlace
Super Micro Computer, Adobe And Nucor Are Among Top Large Cap Losers Last Week (December 9-13): Are The Others In Your Portfolio? - Benzinga
Beigene directors sell shares worth $194.2 million - Investing.com
Beigene president Wu Xiaobin reports $120,894 sale of economic interest By Investing.com - Investing.com South Africa
Beigene president Wu Xiaobin reports $120,894 sale of economic interest - Investing.com
Beigene sees $3.57 billion stock sale by Hillhouse Investment By Investing.com - Investing.com South Africa
Beigene sees $274 million stock sale by Hillhouse Investment By Investing.com - Investing.com
AGFA Gevaert NV (AGFB.BR) Stock Price, News & Analyst Forecast - eToro
Morgan Stanley increases BeiGene stock target on drug prospects - Investing.com
10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey
Beigene's Wang Xiaodong sells shares worth $9.19 million - Investing.com
BeiGene stock outlook positive as Bernstein lifts price target, keeps Market Perform - Investing.com
China ADRs have increased to the largest share since late 2021 – GS - MSN
BeiGene settles patent litigation, extends BRUKINSA exclusivity - Investing.com
10 Biggest Biotechnology Companies - Investopedia
BeiGene announces name change to BeOne Medicines Ltd. - Investing.com
BeiGene shares lift on raised price target to $260 from $254 - Investing.com
UBS Raises BeiGene (BGNE.US) TP to US$289.7 as 3Q Results Beat - AASTOCKS.com
BeiGene shares fall despite better-than-expected Q3 results - Investing.com
BeiGene announces passing of board member Donald Glazer - Investing.com
BEIGENE Senior Staff Reportedly Investigated, but Not Related to Firm Operations - AASTOCKS.com
Indaptus Therapeutics partners with BeiGene for cancer study - Investing.com India
BeiGene stock momentum builds on Brukinsa success, says JPMorgan's Fye - Investing.com
CMBI Eyes Opportunities in Innovative Medical Insurance, Prefers WuXi AppTec/ BeiGene/ INNOVENT BIO/ SKB BIO-B/ GIANT BIOGENE/ 3SBIO/ Mindray Bio-MedicalUS StocksGlobal News Content - AASTOCKS.com
Financial Fitness Check: Examining BeiGene Ltd ADR (BGNE)’s Key Ratios - The Dwinnex
The Potential Rise in the Price of BeiGene Ltd ADR (BGNE) following insiders activity - Knox Daily
Samsara Inc (IOT) may enjoy gains as insiders got busy in the recent days - Knox Daily
Monitoring Ginkgo Bioworks Holdings Inc (DNA) after recent insider movements - Knox Daily
Insider Sale Alert: PepsiCo Inc [PEP] – Is it Time to sell? - Knox Daily
VZIO (VIZIO Holding Corp) may reap gains as insiders became active recently - Knox Daily
Investing in Allegro Microsystems Inc. (ALGM) Is Getting More Attractive - Knox Daily
Investing in Alphatec Holdings Inc (ATEC): What You Must Know - Knox Daily
An Analysis of Mercury Systems Inc (MRCY)’s Potential Price Growth - Knox Daily
XPeng Inc. Sponsored ADR (XPEV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
BeiGene CEO John Oyler sells shares worth over $3.75 million - Investing.com
Royal Caribbean Group [RCL] Shares Rise 5.26 % on Wednesday - Knox Daily
Selling Buzz: UL Solutions Inc [ULS] 10% Owner ULSE Inc. sells 3,000,000 shares of the company - Knox Daily
Director Cui Xiangmin acquire 277,895 shares of Nuvation Bio Inc [NUVB] - Knox Daily
Taking a look at what insiders are doing to gauge the BeiGene Ltd ADR (BGNE)’s direction - Knox Daily
Stock Performance Spotlight: BeiGene Ltd ADR (BGNE) Ends the Day at 240.40, Up by 2.11 - The Dwinnex
Buying Buzz: Vuzix Corporation [VUZI] Director Harned Timothy Heydenreich purchases 20,000 shares of the company - Knox Daily
A company insider recently sold 1,447 shares of uniQure N.V. [QURE]. Should You Sale? - Knox Daily
Director Stark Eugene S acquire 2,500 shares of Prospect Capital Corp [PSEC] - Knox Daily
It makes sense and dollars to buy BeiGene Ltd ADR (BGNE) stock - SETE News
Recent Insider Activity Could Benefit ACI Worldwide Inc (ACIW) - Knox Daily
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Yahoo Finance
Beigene Ltd Adr Stock (BGNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.16%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):